International Society for Cellular Therapy 2018

Posted on April 30, 2018November 10, 2021 by triumvira1

Triumvira will be presenting at ISCT 2018 – May 2-5, 2018 at the Palais des Congrès de Montréal in Montréal, QC, Canada

ISCT is the premier cell therapy translation society focused on pre-clinical, clinical and translational aspects of developing cell therapy products. As such, ISCT helps academic, government and biotech/pharma sectors transform research into practice and product.

ISCT 2018 is expected to draw over 1,600 delegates globally. The Annual Meeting will serve as the prime opportunity for you to network with experts within the global cell therapy arena.

Triumvira Immunologics to Present at Two Upcoming Conferences:

Posted on April 30, 2018November 10, 2021 by triumvira1

International Society for Cellular Therapy and Bloom Burton & Co. Healthcare Investor Conference

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple types of cancers, today announced that it will present an abstract at the International Society for Cellular Therapy Annual Meeting (ISCT) in Montreal, and a company overview at the Bloom Burton & Co. Healthcare Investor Conference in Toronto, both on Thursday, May 3.

At the ISCT, Dr. Chris Helsen, Director of Platform Development, will be presenting during the “Cancer Immunotherapy” breakout plenary on May 3, 11:00am – 12:15pm ET. The abstract is titled T cells engineered with T-Cell Antigen Coupler (TAC) receptors display robust efficacy against solid and liquid tumor xenografts in the absence of any toxicity.

Bloom Burton & Co. Healthcare Investor Conference

Posted on April 12, 2018November 10, 2021 by triumvira1

Triumvira will be presenting at the Bloom Burton & Co. Healthcare Investor Conference on May 2 and 3, 2018 at the Sheraton Centre Toronto Hotel in Toronto, ON., Canada

This year, BBHIC will host approximately 60 of Canada’s premier publicly-traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. Our agenda includes company presentations, keynote sessions and panel discussions by industry leaders.

Triumvira Immunologics Appoints Cynthia Collins to Board of Directors

Posted on April 5, 2018November 10, 2021 by triumvira1

Innovative immuno-therapy company welcomes a recognized leader in life sciences and therapeutics

AUSTIN, Texas & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics, a privately-held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Cynthia (Cindy) Collins to the Board of Directors.

“We are very pleased that Cindy has joined Triumvira,” said President and CEO of Triumvira Immunologics, Paul Lammers. “Cindy brings extensive experience in leading and managing gene and cell therapy companies as well as strategic positioning, oncology drug development and product commercialization. We look forward to her contributions as we build our company and work to bring new treatments to patients in need.”